EurekaMag.com logo
+ Site Statistics
References:
52,725,316
Abstracts:
28,411,598
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

Recombinant derivatives of the major birch pollen allergen Bet v 1, which induce fewer symptoms and lower mediator release and eosinophil activation than rBet v 1 wild-type in nasal challenges in birch pollen allergic patients






Allergy (Copenhagen) 56(Supplement 68): 94

Recombinant derivatives of the major birch pollen allergen Bet v 1, which induce fewer symptoms and lower mediator release and eosinophil activation than rBet v 1 wild-type in nasal challenges in birch pollen allergic patients



Accession: 035619164



Related references

Nasal challenges with recombinant derivatives of the major birch pollen allergen Bet v 1 induce fewer symptoms and lower mediator release than rBet v 1 wild-type in patients with allergic rhinitis. Clinical & Experimental Allergy 32(10): 1448-1453, October, 2002

Comparison of inflammatory responses to genetically engineered hypoallergenic derivatives of the major birch pollen allergen bet v 1 and to recombinant bet v 1 wild type in skin chamber fluids collected from birch pollen-allergic patients. Journal of Allergy and Clinical Immunology 106(1 Pt 1): 101-109, 2000

Oralair Birch, a recombinant major birch pollen allergen tablet for sublingual immunotherapy of allergic rhinitis caused by birch pollen. Current Opinion in Investigational Drugs 11(5): 586-596, 2010

Cytokine and antibody responses in birch-pollen-allergic patients treated with genetically modified derivatives of the major birch pollen allergen Bet v 1. International Archives of Allergy and Immunology 138(1): 59-66, 2005

Recombinant birch pollen allergens (rBet v 1 and rBet v 2) contain most of the IgE epitopes present in birch, alder, hornbeam, hazel, and oak pollen: a quantitative IgE inhibition study with sera from different populations. Journal of Allergy and Clinical Immunology 102(4 Pt 1): 579-591, 1998

Fagales pollen sensitization in a birch-free area: a respiratory cohort survey using Fagales pollen extracts and birch recombinant allergens (rBet v 1, rBet v 2, rBet v 4). Clinical and Experimental Allergy 33(10): 1419-1428, 2003

Skin test evaluation of genetically engineered hypoallergenic derivatives of the major birch pollen allergen, Bet v 1: results obtained with a mix of two recombinant Bet v 1 fragments and recombinant Bet v 1 trimer in a Swedish population before the birch pollen season. Journal of Allergy and Clinical Immunology 104(5): 969-977, 1999

Recombinant Bet v 1, the major birch pollen allergen, induces hypersensitivity reactions equal to those induced by natural Bet v 1 in the airways of patients allergic to tree pollen. Journal of Allergy & Clinical Immunology 99(3): 354-359, 1997

The major birch pollen allergen Bet v 1 induces different responses in dendritic cells of birch pollen allergic and healthy individuals. Plos One 10(1): E0117904-E0117904, 2016

Skin testing with recombinant birch allergens rBET V 1 and rBET V 2 Correlation with detection of specific IGE antibodies by immunoblot of birch pollen. Journal of Allergy & Clinical Immunology 95(1 PART 2): 305, 1995